1. Buckley, S.M.; Casals, J.; Downs, W.G. Isolation and Antigenic Characterization of Lassa Virus. Nature 1970, 227, 174–174, doi:10.1038/227174a0.
2. Bonthius, D.J. Lymphocytic Choriomeningitis Virus: An Underrecognized Cause of Neurologic Disease in the Fetus, Child, and Adult. Semin Pediatr Neurol 2012, 19, 89–95, doi:10.1016/j.spen.2012.02.002.
3. Al-Zein, N.; Boyce, T.G.; Correa, A.G.; Rodriguez, V. Meningitis Caused by Lymphocytic Choriomeningitis Virus in a Patient with Leukemia. J Pediatr Hematol Oncol 2008, 30, 781–784, doi:10.1097/MPH.0b013e318182e72b.
4. Sarute, N.; Ross, S.R. New World Arenavirus Biology. Annu. Rev. Virol. 2017, 4, 141–158, doi:10.1146/annurev-virology-101416-042001.
5. Khan, S.H.; Goba, A.; Chu, M.; Roth, C.; Healing, T.; Marx, A.; Fair, J.; Guttieri, M.C.; Ferro, P.; Imes, T.; et al. New Opportunities for Field Research on the Pathogenesis and Treatment of Lassa Fever. Antiviral Research 2008, 78, 103– 115, doi:10.1016/j.antiviral.2007.11.003.
6. Kofman, A.; Choi, M.J.; Rollin, P.E. Lassa Fever in Travelers from West Africa, 1969–2016. Emerg Infect Dis 2019, 25, 236–239, doi:10.3201/eid2502.180836.
7. Fisher-Hoch, S.P.; Tomori, O.; Nasidi, A.; Perez-Oronoz, G.I.; Fakile, Y.; Hutwagner, L.; McCormick, J.B. Review of Cases of Nosocomial Lassa Fever in Nigeria: The High Price of Poor Medical Practice. BMJ 1995, 311, 857–859, doi:10.1136/bmj.311.7009.857.
8. Walls, B. Lassa Fever and Pregnancy. Midwives Chron 1985, 1168, 136–138.
9. ウイルス性出血熱への行政対応の手引き第二版平成 29 年 6 月 厚生労働 省健康局結核感染症課.
10. Virus Metadata Repository: Version May 18, 2021; MSL36 Available online: https://talk.ictvonline.org/taxonomy/vmr/m/vmr-file-repository/12323 (accessed on 28 October 2021).
11. Tamura, K.; Stecher, G.; Kumar, S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Molecular Biology and Evolution 2021, 38, 3022–3027, doi:10.1093/molbev/msab120.
12. Bowen, M.D.; Peters, C.J.; Nichol, S.T. Phylogenetic Analysis of TheArenaviridae:Patterns of Virus Evolution and Evidence for Cospeciation between Arenaviruses and Their Rodent Hosts. Molecular Phylogenetics and Evolution 1997, 8, 301–316, doi:10.1006/mpev.1997.0436.
13. Downs, W.G.; Anderson, C.R.; Spence, L.; Aitken, T.H.G.; Greenhall, A.H. Tacaribe Virus, a New Agent Isolated from Artibeus Bats and Mosquitoes in Trinidad, West Indies. Am J Trop Med Hyg 1963, 12, 640–646, doi:10.4269/ajtmh.1963.12.640.
14. Sayler, K.A.; Barbet, A.F.; Chamberlain, C.; Clapp, W.L.; Alleman, R.; Loeb, J.C.; Lednicky, J.A. Isolation of Tacaribe Virus, a Caribbean Arenavirus, from HostSeeking Amblyomma Americanum Ticks in Florida. PLoS One 2014, 9, e115769, doi:10.1371/journal.pone.0115769.
15. Carballal, G.; Calello, M.A.; Laguens, R.P.; Weissenbacher, M.C. Tacaribe Virus: A New Alternative for Argentine Hemorrhagic Fever Vaccine. J Med Virol 1987, 23, 257–263, doi:10.1002/jmv.1890230308.
16. Ye, C.; de la Torre, J.C.; Martínez-Sobrido, L. Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus. J Virol 2020, 94, e01014-20, doi:10.1128/JVI.01014-20.
17. Andersen, K.G.; Shapiro, B.J.; Matranga, C.B.; Sealfon, R.; Lin, A.E.; Moses, L.M.; Folarin, O.A.; Goba, A.; Odia, I.; Ehiane, P.E.; et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 2015, 162, 738–750, doi:10.1016/j.cell.2015.07.020.
18. Bowen, M.D.; Rollin, P.E.; Ksiazek, T.G.; Hustad, H.L.; Bausch, D.G.; Demby, A.H.; Bajani, M.D.; Peters, C.J.; Nichol, S.T. Genetic Diversity among Lassa Virus Strains. Journal of Virology 2000, 74, 6992–7004, doi:10.1128/JVI.74.15.6992-7004.2000.
19. Ehichioya, D.U.; Hass, M.; Becker-Ziaja, B.; Ehimuan, J.; Asogun, D.A.; FichetCalvet, E.; Kleinsteuber, K.; Lelke, M.; ter Meulen, J.; Akpede, G.O.; et al. Current Molecular Epidemiology of Lassa Virus in Nigeria▿. J Clin Microbiol 2011, 49, 1157–1161, doi:10.1128/JCM.01891-10.
20. Garnett, L.E.; Strong, J.E. Lassa Fever: With 50 Years of Study, Hundreds of Thousands of Patients and an Extremely High Disease Burden, What Have We Learned? Current Opinion in Virology 2019, 37, 123–131, doi:10.1016/j.coviro.2019.07.009.
21. Whitmer, S.L.M.; Strecker, T.; Cadar, D.; Dienes, H.-P.; Faber, K.; Patel, K.; Brown, S.M.; Davis, W.G.; Klena, J.D.; Rollin, P.E.; et al. New Lineage of Lassa Virus, Togo, 2016. Emerg Infect Dis 2018, 24, 599–602, doi:10.3201/eid2403.171905.
22. Olayemi, A.; Cadar, D.; Magassouba, N.; Obadare, A.; Kourouma, F.; Oyeyiola, A.; Fasogbon, S.; Igbokwe, J.; Rieger, T.; Bockholt, S.; et al. New Hosts of The Lassa Virus. Scientific Reports 2016, 6, 25280, doi:10.1038/srep25280.
23. Fernandes, J.; Guterres, A.; de Oliveira, R.C.; Chamberlain, J.; Lewandowski, K.; Teixeira, B.R.; Coelho, T.A.; Crisóstomo, C.F.; Bonvicino, C.R.; D’Andrea, P.S.; et al. Xapuri Virus, a Novel Mammarenavirus: Natural Reassortment and Increased Diversity between New World Viruses. Emerg Microbes Infect 2018, 7, 120, doi:10.1038/s41426-018-0119-9.
24. Fernandes, J.; Guterres, A.; de Oliveira, R.C.; Jardim, R.; Dávila, A.M.R.; Hewson, R.; de Lemos, E.R.S. Aporé Virus, a Novel Mammarenavirus (Bunyavirales: Arenaviridae) Related to Highly Pathogenic Virus from South America. Mem Inst Oswaldo Cruz 2019, 114, e180586, doi:10.1590/0074- 02760180586.
25. Moreno, H.; Rastrojo, A.; Pryce, R.; Fedeli, C.; Zimmer, G.; Bowden, T.A.; Gerold, G.; Kunz, S. A Novel Circulating Tamiami Mammarenavirus Shows Potential for Zoonotic Spillover. PLoS Negl Trop Dis 2020, 14, e0009004, doi:10.1371/journal.pntd.0009004.
26. Rowe, W.P.; Murphy, F.A.; Bergold, G.H.; Casals, J.; Hotchin, J.; Johnson, K.M.; Lehmann-Grube, F.; Mims, C.A.; Traub, E.; Webb, P.A. Arenoviruses: Proposed Name for a Newly Defined Virus Group. J Virol 1970, 5, 651–652, doi:10.1128/JVI.5.5.651-652.1970.
27. Cao, W.; Henry, M.D.; Borrow, P.; Yamada, H.; Elder, J.H.; Ravkov, E.V.; Nichol, S.T.; Compans, R.W.; Campbell, K.P.; Oldstone, M.B. Identification of Alpha-Dystroglycan as a Receptor for Lymphocytic Choriomeningitis Virus and Lassa Fever Virus. Science 1998, 282, 2079–2081, doi:10.1126/science.282.5396.2079.
28. Spiropoulou, C.F.; Kunz, S.; Rollin, P.E.; Campbell, K.P.; Oldstone, M.B.A. New World Arenavirus Clade C, but Not Clade A and B Viruses, Utilizes AlphaDystroglycan as Its Major Receptor. J Virol 2002, 76, 5140–5146, doi:10.1128/jvi.76.10.5140-5146.2002.
29. Barresi, R.; Campbell, K.P. Dystroglycan: From Biosynthesis to Pathogenesis of Human Disease. J Cell Sci 2006, 119, 199–207, doi:10.1242/jcs.02814.
30. Ibraghimov-Beskrovnaya, O.; Ervasti, J.M.; Leveille, C.J.; Slaughter, C.A.; Sernett, S.W.; Campbell, K.P. Primary Structure of Dystrophin-Associated Glycoproteins Linking Dystrophin to the Extracellular Matrix. Nature 1992, 355, 696–702, doi:10.1038/355696a0.
31. Kanagawa, M.; Saito, F.; Kunz, S.; Yoshida-Moriguchi, T.; Barresi, R.; Kobayashi, Y.M.; Muschler, J.; Dumanski, J.P.; Michele, D.E.; Oldstone, M.B.A.; et al. Molecular Recognition by LARGE Is Essential for Expression of Functional Dystroglycan. Cell 2004, 117, 953–964, doi:10.1016/j.cell.2004.06.003.
32. Kunz, S.; Rojek, J.M.; Kanagawa, M.; Spiropoulou, C.F.; Barresi, R.; Campbell, K.P.; Oldstone, M.B.A. Posttranslational Modification of Alpha-Dystroglycan, the Cellular Receptor for Arenaviruses, by the Glycosyltransferase LARGE Is Critical for Virus Binding. J Virol 2005, 79, 14282–14296, doi:10.1128/JVI.79.22.14282- 14296.2005.
33. Rojek, J.M.; Spiropoulou, C.F.; Campbell, K.P.; Kunz, S. Old World and Clade C New World Arenaviruses Mimic the Molecular Mechanism of Receptor Recognition Used by Alpha-Dystroglycan’s Host-Derived Ligands. J Virol 2007, 81, 5685–5695, doi:10.1128/JVI.02574-06.
34. Sabeti, P.C.; Varilly, P.; Fry, B.; Lohmueller, J.; Hostetter, E.; Cotsapas, C.; Xie, X.; Byrne, E.H.; McCarroll, S.A.; Gaudet, R.; et al. Genome-Wide Detection and Characterization of Positive Selection in Human Populations. Nature 2007, 449, 913–918, doi:10.1038/nature06250.
35. Shimojima, M.; Ströher, U.; Ebihara, H.; Feldmann, H.; Kawaoka, Y. Identification of Cell Surface Molecules Involved in Dystroglycan-Independent Lassa Virus Cell Entry. J Virol 2012, 86, 2067–2078, doi:10.1128/JVI.06451-11.
36. Shimojima, M.; Kawaoka, Y. Cell Surface Molecules Involved in Infection Mediated by Lymphocytic Choriomeningitis Virus Glycoprotein. J Vet Med Sci 2012, 74, 1363–1366, doi:10.1292/jvms.12-0176.
37. Goncalves, A.-R.; Moraz, M.-L.; Pasquato, A.; Helenius, A.; Lozach, P.-Y.; Kunz, S. Role of DC-SIGN in Lassa Virus Entry into Human Dendritic Cells. J Virol 2013, 87, 11504–11515, doi:10.1128/JVI.01893-13.
38. Flanagan, M.L.; Oldenburg, J.; Reignier, T.; Holt, N.; Hamilton, G.A.; Martin, V.K.; Cannon, P.M. New World Clade B Arenaviruses Can Use Transferrin Receptor 1 (TfR1)-Dependent and -Independent Entry Pathways, and Glycoproteins from Human Pathogenic Strains Are Associated with the Use of TfR1. J Virol 2008, 82, 938–948, doi:10.1128/JVI.01397-07.
39. Oppliger, J.; Torriani, G.; Herrador, A.; Kunz, S. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis. J Virol 2016, 90, 6412–6429, doi:10.1128/JVI.00257-16.
40. Li, S.; Sun, Z.; Pryce, R.; Parsy, M.-L.; Fehling, S.K.; Schlie, K.; Siebert, C.A.; Garten, W.; Bowden, T.A.; Strecker, T.; et al. Acidic PH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. PLoS Pathog 2016, 12, e1005418, doi:10.1371/journal.ppat.1005418.
41. Jae, L.T.; Raaben, M.; Herbert, A.S.; Kuehne, A.I.; Wirchnianski, A.S.; Soh, T.K.; Stubbs, S.H.; Janssen, H.; Damme, M.; Saftig, P.; et al. Virus Entry. Lassa Virus Entry Requires a Trigger-Induced Receptor Switch. Science 2014, 344, 1506– 1510, doi:10.1126/science.1252480.
42. Cohen-Dvashi, H.; Cohen, N.; Israeli, H.; Diskin, R. Molecular Mechanism for LAMP1 Recognition by Lassa Virus. J Virol 2015, 89, 7584–7592, doi:10.1128/JVI.00651-15.
43. Hulseberg, C.E.; Fénéant, L.; Szymańska, K.M.; White, J.M. Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments. mBio 2018, doi:10.1128/mBio.01818-17.
44. Markosyan, R.M.; Marin, M.; Zhang, Y.; Cohen, F.S.; Melikyan, G.B. The Late Endosome-Resident Lipid Bis(Monoacylglycero)Phosphate Is a Cofactor for Lassa Virus Fusion. PLoS Pathog 2021, 17, e1009488, doi:10.1371/journal.ppat.1009488.
45. Nunberg, J.H.; York, J. The Curious Case of Arenavirus Entry, and Its Inhibition. Viruses 2012, 4, 83–101, doi:10.3390/v4010083.
46. Eschli, B.; Quirin, K.; Wepf, A.; Weber, J.; Zinkernagel, R.; Hengartner, H. Identification of an N-Terminal Trimeric Coiled-Coil Core within Arenavirus Glycoprotein 2 Permits Assignment to Class I Viral Fusion Proteins. J Virol 2006, 80, 5897–5907, doi:10.1128/JVI.00008-06.
47. Igonet, S.; Vaney, M.-C.; Vonrhein, C.; Vonhrein, C.; Bricogne, G.; Stura, E.A.; Hengartner, H.; Eschli, B.; Rey, F.A. X-Ray Structure of the Arenavirus Glycoprotein GP2 in Its Postfusion Hairpin Conformation. Proc Natl Acad Sci U S A 2011, 108, 19967–19972, doi:10.1073/pnas.1108910108.
48. Shulman, A.; Katz, M.; Cohen-Dvashi, H.; Greenblatt, H.M.; Levy, Y.; Diskin, R. Variations in Core Packing of GP2 from Old World Mammarenaviruses in Their Post-Fusion Conformations Affect Membrane-Fusion Efficiencies. J Mol Biol 2019, 431, 2095–2111, doi:10.1016/j.jmb.2019.04.012.
49. Harrison, S.C. Viral Membrane Fusion. Nat Struct Mol Biol 2008, 15, 690–698, doi:10.1038/nsmb.1456.
50. McCormick, J.B.; King, I.J.; Webb, P.A.; Scribner, C.L.; Craven, R.B.; Johnson, K.M.; Elliott, L.H.; Belmont-Williams, R. Lassa Fever. Effective Therapy with Ribavirin. N Engl J Med 1986, 314, 20–26, doi:10.1056/NEJM198601023140104.
51. Salam, A.P.; Cheng, V.; Edwards, T.; Olliaro, P.; Sterne, J.; Horby, P. Time to Reconsider the Role of Ribavirin in Lassa Fever. PLoS Negl Trop Dis 2021, 15, e0009522, doi:10.1371/journal.pntd.0009522.
52. Eberhardt, K.A.; Mischlinger, J.; Jordan, S.; Groger, M.; Günther, S.; Ramharter, M. Ribavirin for the Treatment of Lassa Fever: A Systematic Review and MetaAnalysis. Int J Infect Dis 2019, 87, 15–20, doi:10.1016/j.ijid.2019.07.015.
53. Oral Ribavirin Treatment of Influenza A and B. | Antimicrobial Agents and Chemotherapy Available online: https://aac.asm.org/content/31/8/1285 (accessed on 1 April 2021).
54. Larson, R.A.; Dai, D.; Hosack, V.T.; Tan, Y.; Bolken, T.C.; Hruby, D.E.; Amberg, S.M. Identification of a Broad-Spectrum Arenavirus Entry Inhibitor. Journal of Virology 2008, 82, 10768–10775, doi:10.1128/JVI.00941-08.
55. Madu, I.G.; Files, M.; Gharaibeh, D.N.; Moore, A.L.; Jung, K.-H.; Gowen, B.B.; Dai, D.; Jones, K.F.; Tyavanagimatt, S.R.; Burgeson, J.R.; et al. A Potent Lassa Virus Antiviral Targets an Arenavirus Virulence Determinant. PLOS Pathogens 2018, 14, e1007439, doi:10.1371/journal.ppat.1007439.
56. Oestereich, L.; Rieger, T.; Lüdtke, A.; Ruibal, P.; Wurr, S.; Pallasch, E.; Bockholt, S.; Krasemann, S.; Muñoz-Fontela, C.; Günther, S. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J Infect Dis 2016, 213, 934–938, doi:10.1093/infdis/jiv522.
57. Urata, S.; Yun, N.; Pasquato, A.; Paessler, S.; Kunz, S.; Torre, J.C. de la Antiviral Activity of a Small-Molecule Inhibitor of Arenavirus Glycoprotein Processing by the Cellular Site 1 Protease. Journal of Virology 2011, 85, 795–803, doi:10.1128/JVI.02019-10.
58. Pasquato, A.; Rochat, C.; Burri, D.J.; Pasqual, G.; la Torre, J.C. de; Kunz, S. Evaluation of the Anti-Arenaviral Activity of the Subtilisin Kexin Isozyme-1/Site1 Protease Inhibitor PF-429242. Virology 2012, 423, 14–22, doi:10.1016/j.virol.2011.11.008.
59. Zhang, X.; Tang, K.; Guo, Y. The Antifungal Isavuconazole Inhibits the Entry of Lassa Virus by Targeting the Stable Signal Peptide-GP2 Subunit Interface of Lassa Virus Glycoprotein. Antiviral Res 2020, 174, 104701, doi:10.1016/j.antiviral.2019.104701.
60. Zhang, X.; Yan, F.; Tang, K.; Chen, Q.; Guo, J.; Zhu, W.; He, S.; Banadyga, L.; Qiu, X.; Guo, Y. Identification of a Clinical Compound Losmapimod That Blocks Lassa Virus Entry. Antiviral Research 2019, 167, 68–77, doi:10.1016/j.antiviral.2019.03.014.
61. Wang, P.; Liu, Y.; Zhang, G.; Wang, S.; Guo, J.; Cao, J.; Jia, X.; Zhang, L.; Xiao, G.; Wang, W. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. Journal of Virology 2018, 92, doi:10.1128/JVI.00954-18.
62. Garbutt, M.; Liebscher, R.; Wahl-Jensen, V.; Jones, S.; Möller, P.; Wagner, R.; Volchkov, V.; Klenk, H.-D.; Feldmann, H.; Ströher, U. Properties of ReplicationCompetent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses. J Virol 2004, 78, 5458–5465, doi:10.1128/jvi.78.10.5458-5465.2004.
63. Wolff, S.; Schultze, T.; Fehling, S.K.; Mengel, J.P.; Kann, G.; Wolf, T.; Eickmann, M.; Becker, S.; Hain, T.; Strecker, T. Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany. Genome Announc 2016, 4, doi:10.1128/genomeA.00938-16.
64. World Health Organization. 2002. WHO Manual on Animal Influenza Diagnosis and Surveillance. World Health Organization, Geneva, Switzerland:
65. Reed, L.J.; Muench, H. A Simple Method of Estimating Fifty per Cent Endopoints. American Journal of Epidemiology 1938, 27, 493–497, doi:10.1093/oxfordjournals.aje.a118408.
66. Rasmussen, T.B.; Uttenthal, Å.; Fernández, J.; Storgaard, T. Quantitative Multiplex Assay for Simultaneous Detection and Identification of Indiana and New Jersey Serotypes of Vesicular Stomatitis Virus. J Clin Microbiol 2005, 43, 356– 362, doi:10.1128/JCM.43.1.356-362.2005.
67. Kajiji, S.; Dreslin, J.A.; Grizzuti, K.; Gros, P. Structurally Distinct MDR Modulators Show Specific Patterns of Reversal against P-Glycoproteins Bearing Unique Mutations at Serine939/941. Biochemistry 1994, 33, 5041–5048, doi:10.1021/bi00183a006.
68. Zhang, null; Chung, null; Oldenburg, null A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999, 4, 67–73, doi:10.1177/108705719900400206.
69. Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the Role of ABC Transporters in Multidrug-Resistant Cancer. Nat Rev Cancer 2018, 18, 452–464, doi:10.1038/s41568-018-0005-8.
70. Mollazadeh, S.; Sahebkar, A.; Hadizadeh, F.; Behravan, J.; Arabzadeh, S. Structural and Functional Aspects of P-Glycoprotein and Its Inhibitors. Life Sciences 2018, 214, 118–123, doi:10.1016/j.lfs.2018.10.048.
71. Waghray, D.; Zhang, Q. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. J Med Chem 2018, 61, 5108–5121, doi:10.1021/acs.jmedchem.7b01457.
72. Hernandez, H.W.; Soeung, M.; Zorn, K.M.; Ashoura, N.; Mottin, M.; Andrade, C.H.; Caffrey, C.R.; de Siqueira-Neto, J.L.; Ekins, S. High Throughput and Computational Repurposing for Neglected Diseases. Pharm Res 2018, 36, 27, doi:10.1007/s11095-018-2558-3.
73. Bai, J.P.F. Pharmacodynamics and Systems Pharmacology Approaches to Repurposing Drugs in the Wake of Global Health Burden. J Pharm Sci 2016, 105, 3007–3012, doi:10.1016/j.xphs.2016.07.004.
74. Li, M.; de Graaf, I.A.M.; Siissalo, S.; de Jager, M.H.; van Dam, A.; Groothuis, G.M.M. The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices. Drug Metab Dispos 2016, 44, 683–691, doi:10.1124/dmd.115.068684.
75. Raviv, Y.; Puri, A.; Blumenthal, R. P-Glycoprotein-Overexpressing MultidrugResistant Cells Are Resistant to Infection by Enveloped Viruses That Enter via the Plasma Membrane1. The FASEB Journal 2000, 14, 511–515, doi:10.1096/fasebj.14.3.511.
76. Larkin, M.A.; Blackshields, G.; Brown, N.P.; Chenna, R.; McGettigan, P.A.; McWilliam, H.; Valentin, F.; Wallace, I.M.; Wilm, A.; Lopez, R.; et al. Clustal W and Clustal X Version 2.0. Bioinformatics 2007, 23, 2947–2948, doi:10.1093/bioinformatics/btm404.
77. Robert, X.; Gouet, P. Deciphering Key Features in Protein Structures with the New ENDscript Server. Nucleic Acids Research 2014, 42, W320–W324, doi:10.1093/nar/gku316. 78. R&D Blueprint Available online: https://www.who.int/teams/health-product-andpolicy-standards/about/blueprint (accessed on 13 December 2021).